Skip to main content
SpringerLink
Log in

Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors

  • Review
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

Tyrosine kinase inhibitors (TKIs) have dramatically changed the treatment of chronic myeloid leukemia (CML) and are increasingly used in other malignancies. Despite the apparent selectivity of these agents significant side effects can occur mainly due to off target kinase inhibition. Clinical consequences of serosal inflammation, including pleural and pericardial effusions, have emerged as a frequent adverse event associated with dasatinib while occurring much less frequently during imatinib and nilotinib therapy. The pathogenesis is uncertain but may involve inhibition of platelet derived growth factor or expansion of cytotoxic T and natural killer cells. The development of serosal inflammation with dasatinib poses a significant challenge to physicians, as it cannot be predicted, the time of onset is variable, and management frequently requires repeat invasive procedures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Druker BJ et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408–2417

    Article  CAS  PubMed  Google Scholar 

  2. Shah NP et al (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2(2):117–125

    Article  CAS  PubMed  Google Scholar 

  3. Gorre ME et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531):876–880

    Article  CAS  PubMed  Google Scholar 

  4. Jabbour E et al (2007) Current and emerging treatment options in chronic myeloid leukemia. Cancer 109(11):2171–2181

    Article  CAS  PubMed  Google Scholar 

  5. Kantarjian HM et al (2006) New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 145(12):913–923

    PubMed  Google Scholar 

  6. Kantarjian H et al (2007) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109(12):5143–5150

    Article  CAS  PubMed  Google Scholar 

  7. Talpaz M et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354(24):2531–2541

    Article  CAS  PubMed  Google Scholar 

  8. Shah NP et al (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305(5682):399–401

    Article  CAS  PubMed  Google Scholar 

  9. Nam S et al (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65(20):9185–9189

    Article  CAS  PubMed  Google Scholar 

  10. Hochhaus A et al (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109(6):2303–2309

    Article  CAS  PubMed  Google Scholar 

  11. Shah NP et al (2008) Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26(19):3204–3212

    Article  CAS  PubMed  Google Scholar 

  12. Quintas-Cardama A et al (2007) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25(25):3908–3914

    Article  CAS  PubMed  Google Scholar 

  13. Kantarjian HM et al (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110(10):3540–3546

    Article  CAS  PubMed  Google Scholar 

  14. Bergeron A et al (2007) Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 176(8):814–818

    Article  CAS  PubMed  Google Scholar 

  15. de Lavallade H et al (2008) Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 141(5):745–747

    Article  PubMed  Google Scholar 

  16. Kim D et al (2008) Pleural effusion in dasatinib-treated chronic myeloid leukemia patients after imatinib failure. ASH Annual Meeting Abstracts 112(11):4270

    Google Scholar 

  17. Cortes J et al (2008) Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 22(12):2176–2183

    Article  CAS  PubMed  Google Scholar 

  18. Posadas EM et al (2007) A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer 110(2):309–317

    Article  CAS  PubMed  Google Scholar 

  19. Lombardo LJ et al (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47(27):6658–6661

    Article  CAS  PubMed  Google Scholar 

  20. Buchdunger E et al (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295(1):139–145

    CAS  PubMed  Google Scholar 

  21. Deininger MW (2008) Nilotinib. Clin Cancer Res 14(13):4027–4031

    Article  CAS  PubMed  Google Scholar 

  22. Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79(4):1283–1316

    CAS  PubMed  Google Scholar 

  23. Lindahl P et al (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277(5323):242–245

    Article  CAS  PubMed  Google Scholar 

  24. Jayson GC et al (2005) Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23(5):973–981

    Article  CAS  PubMed  Google Scholar 

  25. Wilhelm SM et al (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7(10):3129–3140

    Article  CAS  PubMed  Google Scholar 

  26. Strumberg D et al (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12(4):426–437

    Article  CAS  PubMed  Google Scholar 

  27. Laird AD et al (2002) SU6668 inhibits Flk-1/KDR and PDGFR{beta} in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 16(7):681–690

    CAS  PubMed  Google Scholar 

  28. Wallez Y et al (2007) Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site. Oncogene 26(7):1067–1077

    Article  CAS  PubMed  Google Scholar 

  29. Luton F et al (1999) The SRC family protein tyrosine kinase p62yes controls polymeric IgA transcytosis in vivo. Mol Cell 4(4):627–632

    Article  CAS  PubMed  Google Scholar 

  30. Rix U et al (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110(12):4055–4063

    Article  CAS  PubMed  Google Scholar 

  31. Matsuyama W et al (2005) Involvement of discoidin domain receptor 1 in the deterioration of pulmonary sarcoidosis. Am J Respir Cell Mol Biol 33(6):565–573

    Article  CAS  PubMed  Google Scholar 

  32. Sakamoto O et al (2001) Expression of discoidin domain receptor 1 tyrosine kinase on the human bronchial epithelium. Eur Respir J 17(5):969–974

    Article  CAS  PubMed  Google Scholar 

  33. Berg LJ et al (2005) Tec family kinases in T lymphocyte development and function. Annu Rev Immunol 23:549–600

    Article  CAS  PubMed  Google Scholar 

  34. Lindvall JM et al (2005) Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev 203:200–215

    Article  CAS  PubMed  Google Scholar 

  35. Kawakami Y et al (1999) Functions of Bruton's tyrosine kinase in mast and B cells. J Leukoc Biol 65(3):286–290

    CAS  PubMed  Google Scholar 

  36. Mustjoki S et al (2008) Clonal expansion of T/NK-Cells during tyrosine kinase inhibitor dasatinib therapy. ASH Annual Meeting Abstracts 112(11):573

    Google Scholar 

  37. Mustjoki S et al (2007) Clonal large granular lymphocyte (LGL) expansion associated with dasatinib therapy. ASH Annual Meeting Abstracts 110(11):2938

    Google Scholar 

  38. Druker BJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031–1037

    Article  CAS  PubMed  Google Scholar 

  39. le Coutre PD, 11 et al (2008) Occurrence of pleural/pericardial effusions in Ph + CML patients failing prior tyrosine kinase inhibitors (TKI) before starting nilotinib—retrospective analysis upon entry into the nilotinib compassionate use program. ASH Annual Meeting Abstracts 112:4271

    Google Scholar 

  40. Breccia M et al (2005) Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib. Eur J Haematol 74(1):89–90

    Article  PubMed  Google Scholar 

  41. Barton JC et al (2002) Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia. Am J Hematol 71(2):139–140

    Article  PubMed  Google Scholar 

  42. Hazarika M et al (2008) Tasigna for chronic and accelerated phase Philadelphia chromosome—positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 14(17):5325–5331

    Article  CAS  PubMed  Google Scholar 

  43. Weisberg E et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7(2):129–141

    Article  CAS  PubMed  Google Scholar 

  44. Puttini M et al (2006) In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl + neoplastic cells. Cancer Res 66(23):11314–11322

    Article  CAS  PubMed  Google Scholar 

  45. Cortes J et al (2008) Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph + chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib. ASH Annual Meeting Abstracts 112(11):1098

    Google Scholar 

  46. Hochhaus A et al (2008) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22(6):1200–1206

    Article  CAS  PubMed  Google Scholar 

  47. Cortes J et al (2008) Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). ASH Annual Meeting Abstracts 112(11):182

    Google Scholar 

  48. Rosti G et al (2008) High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: results of a phase II trial of the GIMEMA CML Working Party. ASH Annual Meeting Abstracts 112(11):181

    Google Scholar 

  49. Stephens J et al (2007) The cost of managing pleural effusion associated with dasatinib in CML patients post imatinib failure. ASH Annual Meeting Abstracts 110(11):4586

    Google Scholar 

  50. Hu Y et al (2004) Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 36(5):453–461

    Article  CAS  PubMed  Google Scholar 

  51. Cortes J et al (2006) Dasatinib (SPRYCEL®) in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CML-CP). ASH Annual Meeting Abstracts 108(11):2161

    Google Scholar 

Download references

Conflict of interest statement

No funds were received in support of this study.

Author information

Authors and Affiliations

  1. Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, TX, USA

    Kevin Kelly, Ronan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan & Francis J. Giles

Authors
  1. Kevin Kelly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronan Swords
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Devalingam Mahalingam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Swaminathan Padmanabhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francis J. Giles
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kevin Kelly.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kelly, K., Swords, R., Mahalingam, D. et al. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Targ Oncol 4, 99–105 (2009). https://doi.org/10.1007/s11523-009-0110-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-009-0110-4

Keywords

Search

Navigation